HEDGE FUNDS-NEWS

11 Best Mid-cap Healthcare Stocks to Buy According to Hedge Funds

Published on July 9, 2025 at 12:52 am by BOB KARR in Hedge Funds, News

Telix Pharmaceuticals Limited (NASDAQ:TLX)

Market Cap as of July 3: $5.37 billion

Number of Hedge Fund Holders: N/A

Telix Pharmaceuticals Limited (NASDAQ:TLX) is one of the 11 Best Mid-cap Healthcare Stocks to Buy According to Hedge Funds. The research firm stated that Telix Pharmaceuticals Limited (NASDAQ:TLX) is the most diversified, comprehensively positioned, and standalone publicly-traded radiopharmaceuticals company. The firm also cited the commercial-stage portfolio of targeted radiotherapy agents catering to the unmet needs in oncology. The company announced that its next-generation PSMA-PET imaging agent for prostate cancer, Gozellix® (kit for the preparation of gallium-68 (68Ga) gozetotide injection), is commercially available nationally in the US.

Telix Pharmaceuticals Limited (NASDAQ:TLX) highlighted that Gozellix builds on proven diagnostic excellence to offer early and accurate detection of metastases at initial staging, with 90% specificity. Telix Pharmaceuticals Limited (NASDAQ:TLX) remains focused on innovation in PSMA imaging, and Gozellix was the result of this commitment. It provides a new level of flexibility in distribution, production, and scheduling, together with a high standard of service and reliability.

Notably, PSMA-PET imaging has been established as the standard of care for staging and identifying biochemical recurrence of prostate cancer. That being said, only a relatively small fraction of 3.4 million men having prostate cancer in the US benefited, mainly due to access and availability challenges. Gozellix’s enhanced formulation provides a greater level of patient access as well as convenience via an extended transportation distance and clinical administration window. Telix Pharmaceuticals Limited (NASDAQ:TLX)’s stock has a consensus price objective of $22.92.

US$22.92 = AUD$35.07